Explore

Companies

Drugs

/

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Oncology/Recurrent B Acute Lymphoblastic Leukemia

Recurrent B Acute Lymphoblastic Leukemia

22

Pipeline Programs↗

6

Active Trials↗

14

Companies Involved↗

Recurrent B Acute Lymphoblastic Leukemia is an emerging landscape with 22 programs across 14 companies. 14 programs are in Phase 3.

Intelligence

Pipeline Metrics

Competitive Density

49/100

Pipeline Velocity

15/100

Mech. Concentration

14/100

Completion Rate

N/A

Attrition Rate

0/100

Pipeline

Programs by Phase

Preclinical

No programs

Phase 15

Venetoclax

AbbVie

Pomalidomide

Karuna Therapeutics, Inc., a Bristol Myers Squibb company

Fludarabine

Sanofi

Ipilimumab

Bristol-Myers Squibb

Nivolumab

Bristol-Myers Squibb

Phase 23

Asparaginase Erwinia Chrysanthemi

St. Jude Children's Research Hospital

Calaspargase Pegol

Servier

Inotuzumab Ozogamicin

Wyeth-Lederle Vaccines

Phase 314

Cyclophosphamide

Baxter Healthcare Corporation

Asparaginase

Dutch Childhood Oncology Group

Blinatumomab

Amgen

Cytarabine

Teva

Dexamethasone

Aspen Global Incorporated

Approved

No programs

Analysis

Modality Breakdown

67%

Small molecule

14 of 21 classified programs — the dominant modality here.

Small molecule leads; the ring shows all 21 classified programs, each share of the total. Modality classified for 95% of 22 pipeline programs.

Analysis

Trial Status

6

clinical trials

Active, not recruiting3 · 50%

Recruiting2 · 33%

Not yet recruiting1 · 17%

Clinical Trials

Trial Activity

6 trials

A Single-Center, Single-Arm, Phase 1 Pilot Study of Pomalidomide Following CD19-Directed Chimeric Antigen Receptor T-Cell Therapy in Relapsed/Refractory CD19+ B-Cell Leukemias and Lymphomas

Recruiting·UUniversity of Michigan Rogel Cancer Center·Phase 1·NCT07532525·12 enrolled

A Phase 1/1b Study Evaluating Asparaginase Erwinia Chrysanthemi- Recombinant-Rywn (Recombinant Erwinia Asparaginase) and Venetoclax in Combination With Blinatumomab in Adults With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia

Recruiting·CCity of Hope Medical Center·Phase 1·NCT07133997·26 enrolled

A Phase 1 Study of Blinatumomab in Combination With Checkpoint Inhibitor(s) of PD-1 (Nivolumab) or Both PD-1 (Nivolumab) and CTLA-4 (Ipilimumab) in Patients With Poor-Risk, Relapsed or Refractory CD19+ Precursor B-Lymphoblastic Leukemia

Active, not recruiting·National Cancer Institute (NCI)·Phase 1·NCT02879695·28 enrolled

A Phase 2 Study of Inotuzumab Ozogamicin (NSC# 772518) in Children and Young Adults With Relapsed or Refractory CD22+ B-Acute Lymphoblastic Leukemia (B-ALL)

Active, not recruiting·Children's Oncology Group·Phase 2·NCT02981628·80 enrolled

Risk-Stratified Randomized Phase III Testing of Blinatumomab (NSC#765986) in First Relapse of Childhood B-Lymphoblastic Leukemia (B-ALL)

Active, not recruiting·National Cancer Institute (NCI)·Phase 3·NCT02101853·669 enrolled

A Phase 1 Study to Evaluate BAFFR-Targeting CAR T Cells for Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia

Not yet recruiting·CCity of Hope Medical Center·Phase 1·NCT07758673·16 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)